Tiny biotech just won the only FDA approved one-time treatment for a solid-tumor cancer. There shares are trading for around $11.00. Who is this company that Jovine keeps talking about for a possible takeover within the next 90 days? Jovine also is predicting that the shares will sell for North of $30.

**Bottom-line 🎯:** The tiny biotech that “Dylan Jovine” has repeatedly flagged as his #1 takeover target is **Iovance Biotherapeutics (NASDAQ: IOVA)**. Jovine argues that the company’s newly FDA-approved, one-time T-cell therapy for melanoma (Amtagvi®) makes it a prime acquisition candidate, and he envisions a path to north of $30 per share within 90 days. While the headline catalyst is real, the stock’s current price action and technical signals suggest the ride will likely be bumpy rather than a straight line to $30. 🚀⚠️ --- ### Why Jovine is so excited 🤔 1. **First-in-class approval:** On Feb 16 2024 the FDA granted accelerated approval to Iovance’s lifileucel (Amtagvi) for advanced melanoma, marking the first FDA-approved cell therapy for any solid tumor . 2. **Scarcity value:** At the time of Jovine’s pitch, IOVA was “100× smaller than Merck (MRK)” yet owned the only FDA nod for a one-time solid-tumor treatment, putting it on every big-pharma’s radar . 3. **Takeover chatter:** IOVA’s shares already spiked 40 % on buy-out rumors in 2020, showing that acquirers do pay up for TIL technology . 4. **Street split:** Barclays just lifted its target to $10 while Goldman Sachs remains at $1 after flagging adoption friction at treatment centers . --- ### What the tape is telling us 📈 • **Latest close:** $2.48, up 0.81 % on Dec 19 2025 . |market_code|code|Ticker|Name|Date|Closing Price| |---|---|---|---|---|---| |185|IOVA|IOVA.O|Iovance|20251218|2.46| • **Short-term trend:** 14-day bullish streak, but only 52 % probability of continuation . • **Support/Resistance:** Price is wedged between $2.42 (wide resistance) and $2.55 (narrow resistance); the model flashes a “Sell” bias . • **Insider sentiment:** CEO and officers exercised and surrendered shares at ~$2.21–$2.23, signaling they’re happy to monetize near current levels . --- ### Putting it together 🧩 Jovine’s thesis rests on an M&A premium that could theoretically push the share price toward his $30 target. However, the stock is still digesting its own approval and hasn’t even reached the $11 level cited in the question (that price may reflect an older, pre-approval period). Until Iovance demonstrates brisk patient infusions and clears operational bottlenecks, the path to a takeover premium will depend heavily on: • Successful commercial rollout of Amtagvi • Positive data read-outs for TIL therapy in other solid tumors (e.g., NSCLC, cervical) • A macro environment where big pharma is willing to pay up for cell-therapy IP Given the current $2-plus trading range and bearish technical overlay, any near-term rally is more likely to be a swing toward resistance than an immediate triple-digit move. Patience—and a healthy risk budget—are essential. 🧘‍♂️💡 --- **Curious next step 🤓:** If you were sitting across the table from an IOVA executive today, what single metric—infusion rate, manufacturing cost, or pipeline data—would you demand to see before betting on that $30 takeover price? Let’s swap ideas! 💬